S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:TLC

Taiwan Liposome Stock Forecast, Price & News

$4.93
+0.03 (+0.61 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.86
Now: $4.93
$5.42
50-Day Range
$4.40
MA: $5.21
$5.81
52-Week Range
$2.48
Now: $4.93
$12.65
Volume32,565 shs
Average Volume29,102 shs
Market Capitalization$182.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III trial for knee osteoarthritis pain. The company's product candidates also comprises TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that is in Phase II clinical trial for post-surgical pain management; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; and TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.

Headlines

Brooks-TLC Hospital puts Irving campus on the market
December 22, 2020 |  bizjournals.com
TLC results, live match coverage
December 20, 2020 |  msn.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLC
CUSIPN/A
CIKN/A
Phone886-2-2655-7377
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.99 million
Book Value$0.65 per share

Profitability

Net Income$-27,000,000.00
Net Margins-894.62%

Miscellaneous

Market Cap$182.89 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.20 out of 5 stars

Medical Sector

885th out of 1,972 stocks

Pharmaceutical Preparations Industry

424th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$4.93
+0.03 (+0.61 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TLC News and Ratings via Email

Sign-up to receive the latest news and ratings for TLC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Taiwan Liposome (NASDAQ:TLC) Frequently Asked Questions

Is Taiwan Liposome a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taiwan Liposome in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Taiwan Liposome stock.
View analyst ratings for Taiwan Liposome
or view top-rated stocks.

What stocks does MarketBeat like better than Taiwan Liposome?

Wall Street analysts have given Taiwan Liposome a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Taiwan Liposome wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Taiwan Liposome?

Taiwan Liposome saw a drop in short interest during the month of February. As of February 12th, there was short interest totaling 100 shares, a drop of 90.0% from the January 28th total of 1,000 shares. Based on an average daily trading volume, of 26,500 shares, the short-interest ratio is presently 0.0 days.
View Taiwan Liposome's Short Interest
.

When is Taiwan Liposome's next earnings date?

Taiwan Liposome is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Taiwan Liposome
.

How were Taiwan Liposome's earnings last quarter?

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) announced its quarterly earnings results on Wednesday, October, 28th. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.06. The firm had revenue of $2.28 million for the quarter, compared to analyst estimates of $0.38 million. Taiwan Liposome had a negative trailing twelve-month return on equity of 136.95% and a negative net margin of 894.62%.
View Taiwan Liposome's earnings history
.

How has Taiwan Liposome's stock price been impacted by Coronavirus (COVID-19)?

Taiwan Liposome's stock was trading at $3.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TLC shares have increased by 28.1% and is now trading at $4.93.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TLC?

2 Wall Street analysts have issued 12 month target prices for Taiwan Liposome's shares. Their forecasts range from $11.00 to $12.00. On average, they expect Taiwan Liposome's stock price to reach $11.50 in the next year. This suggests a possible upside of 133.3% from the stock's current price.
View analysts' price targets for Taiwan Liposome
or view top-rated stocks among Wall Street analysts.

Who are Taiwan Liposome's key executives?

Taiwan Liposome's management team includes the following people:
  • Dr. Keelung Hong, Founder, Chairman & CEO (Age 78)
  • Mr. Zhi-Hong Yeh M.B.A., Pres (Age 49)
  • Ms. Ru-Yun Lin M.B.A., CFO and VP of Fin. & Admin. (Age 55)
  • Dr. George Spencer-Green M.D., M.S., Chief Medical Officer (Age 74)
  • Dr. Yunlong Tseng Ph.D., VP of R&D (Age 55)
  • Dr. Vincent Chang B.Sc. (Chem), Ph.D., M.Sc., VP of Manufacturing Devel.
  • Carina Chen, Principal Financial Officer & Principal Accounting Officer
  • Mr. Thomas H. Bliss Jr., M.B.A., Chief Bus. Officer

Who are some of Taiwan Liposome's key competitors?

What other stocks do shareholders of Taiwan Liposome own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taiwan Liposome investors own include Gilead Sciences (GILD), Pfizer (PFE), Wells Fargo & Company (WFC), Agnico Eagle Mines (AEM), Applied Genetic Technologies (AGTC), Celldex Therapeutics (CLDX), Seabridge Gold (SA), Trevena (TRVN), AbbVie (ABBV) and Advanced Micro Devices (AMD).

When did Taiwan Liposome IPO?

(TLC) raised $29 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 5,000,000 shares at a price of $5.80 per share. Cantor served as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

What is Taiwan Liposome's stock symbol?

Taiwan Liposome trades on the NASDAQ under the ticker symbol "TLC."

Who are Taiwan Liposome's major shareholders?

Taiwan Liposome's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jane Street Group LLC (0.05%) and Renaissance Technologies LLC (0.04%).

Which institutional investors are selling Taiwan Liposome stock?

TLC stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC.

Which institutional investors are buying Taiwan Liposome stock?

TLC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Taiwan Liposome?

Shares of TLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taiwan Liposome's stock price today?

One share of TLC stock can currently be purchased for approximately $4.93.

How much money does Taiwan Liposome make?

Taiwan Liposome has a market capitalization of $182.89 million and generates $6.99 million in revenue each year. The company earns $-27,000,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

What is Taiwan Liposome's official website?

The official website for Taiwan Liposome is www.tlcbio.com.

Where are Taiwan Liposome's headquarters?

Taiwan Liposome is headquartered at 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503.

How can I contact Taiwan Liposome?

Taiwan Liposome's mailing address is 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company can be reached via phone at 886-2-2655-7377 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.